Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Medtronic
Citi
Fuji
Baxter
Argus Health
Cipla
Healthtrust
Daiichi Sankyo

Generated: January 22, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207027

« Back to Dashboard

NDA 207027 describes PROMACTA KIT, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug. Additional details are available on the PROMACTA KIT profile page.

The generic ingredient in PROMACTA KIT is eltrombopag olamine. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the eltrombopag olamine profile page.
Summary for 207027
Tradename:PROMACTA KIT
Applicant:Novartis Pharms Corp
Ingredient:eltrombopag olamine
Patents:8
Formulation / Manufacturing:see details
Pharmacology for NDA: 207027
Mechanism of ActionThrombopoietin Receptor Agonists
Organic Anion Transporting Polypeptide 1B1 Inhibitors
Breast Cancer Resistance Protein Inhibitors
UGT1A1 Inhibitors
UGT1A3 Inhibitors
UGT1A4 Inhibitors
UGT1A6 Inhibitors
UGT1A9 Inhibitors
UGT2B7 Inhibitors
UGT2B15 Inhibitors
Physiological EffectIncreased Megakaryocyte Maturation
Increased Platelet Production
Suppliers and Packaging for NDA: 207027
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PROMACTA KIT eltrombopag olamine FOR SUSPENSION;ORAL 207027 NDA Novartis Pharmaceuticals Corporation 0078-0972 0078-0972-61 1 CARTON in 1 KIT (0078-0972-61) > 30 PACKET in 1 CARTON (0078-0972-23) > 1 POWDER, FOR SUSPENSION in 1 PACKET (0078-0972-19)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrengthEQ 25MG ACID/PACKET
Approval Date:Aug 24, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Jun 11, 2018
Regulatory Exclusivity Use:DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP
Regulatory Exclusivity Expiration:Jun 11, 2018
Regulatory Exclusivity Use:INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.
Regulatory Exclusivity Expiration:Dec 11, 2018
Regulatory Exclusivity Use:PEDIATRIC EXCLUSIVITY

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Cantor Fitzgerald
Johnson and Johnson
Baxter
Argus Health
Julphar
Merck
Chinese Patent Office
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.
Links

Follow DrugPatentWatch: